Joint associations of adiposity and alcohol consumption with liver disease-related morbidity and mortality risk: findings from the UK Biobank

İnan-Eroğlu, Elif; Huang, Bo-Huei; Ahmadi, Matthew; Johnson, Nathan A.; El‐Omar, Emad; Stamatakis, Emmanuel

doi:10.1038/s41430-021-00923-4

Cited by 18 publications

(17 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We conducted a stratified analysis to explore potential modification effects by the following factors: age (<60 or ≥ 60 years), sex, BMI (<30 or ≥30 kg/m 2 ), ever smoke, diet quality score (<3 or ≥3), regular physical activity and respiratory disease. The UK alcohol guidelines recommended alcohol consumption of less than 16 g/day for both men and women, 25 we therefore conducted subgroup analyses within strata of alcohol consumption by the cut point of 16 g/day. For the above analyses, we examined the associations in terms of each IQR increase in air pollution score, and interactions were assessed by inserting product terms into Cox models.…”

Section: Methodsmentioning

confidence: 99%

“…According to previously validated definitions, NAFLD and cirrhosis were defined by self-reported diagnoses, inpatient records and death register. 25 Self-reported diagnoses were only used to capture prevalent NAFLD and cirrhosis at baseline. UK Biobank recorded follow-up health outcomes using International Classification of Diseases 10th revision (ICD-10).…”

Section: Assessment Of Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis: A cohort study

Liao

Zhu

et al. 2022

Liver International

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD), as a liver disease which ranges from simple steatosis to progressive non-alcoholic steatohepatitis that is not caused by excessive alcohol consumption or secondary fat accumulation, is associated with liver-related cancer, cardiovascular events and premature death. 1,2 NAFLD is one of the most prevalent metabolic liver disease, 3 and has been estimated to affect 25-45% adults across different populations. 4,5 Despite extensive investigation on understanding the pathophysiology of NAFLD, there are currently no approved therapies, 6,7 and therefore research has been focusing on various modifiable

show abstract

Section: Methodsmentioning

confidence: 99%

Section: Assessment Of Outcomesmentioning

confidence: 99%

Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis: A cohort study

Liao

Zhu

et al. 2022

Liver International

View full text Add to dashboard Cite

show abstract

“… 1 – 6 According to the history of alcohol intake, fatty liver is artificially categorized into two common forms: alcohol-associated liver disease (ALD) and non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH). 4 , 7 – 10 While ALD is defined by the presence of hepatic steatosis associated with significant alcohol consumption, NAFL is a generic term that includes a series of liver diseases with different injury severities and consequent fibrosis. 4 , 9 Among these, hepatic steatosis is referred to as NAFL, which is defined as the composition of fat that takes up 5–10% of the liver’s weight.…”

Section: Introductionmentioning

confidence: 99%

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

Poulsen

et al. 2022

Sig Transduct Target Ther

133

View full text Add to dashboard Cite

Non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH) has become the leading cause of liver disease worldwide. NASH, an advanced form of NAFL, can be progressive and more susceptible to developing cirrhosis and hepatocellular carcinoma. Currently, lifestyle interventions are the most essential and effective strategies for preventing and controlling NAFL without the development of fibrosis. While there are still limited appropriate drugs specifically to treat NAFL/NASH, growing progress is being seen in elucidating the pathogenesis and identifying therapeutic targets. In this review, we discussed recent developments in etiology and prospective therapeutic targets, as well as pharmacological candidates in pre/clinical trials and patents, with a focus on diabetes, hepatic lipid metabolism, inflammation, and fibrosis. Importantly, growing evidence elucidates that the disruption of the gut–liver axis and microbe-derived metabolites drive the pathogenesis of NAFL/NASH. Extracellular vesicles (EVs) act as a signaling mediator, resulting in lipid accumulation, macrophage and hepatic stellate cell activation, further promoting inflammation and liver fibrosis progression during the development of NAFL/NASH. Targeting gut microbiota or EVs may serve as new strategies for the treatment of NAFL/NASH. Finally, other mechanisms, such as cell therapy and genetic approaches, also have enormous therapeutic potential. Incorporating drugs with different mechanisms and personalized medicine may improve the efficacy to better benefit patients with NAFL/NASH.

show abstract

“…However, another observational study in the United States has revealed race-associated differences in the mortalities due to alcohol-related cirrhosis and liver cancer: White Americans, Native Americans, and Hispanics manifest the highest mortalities from cirrhosis (Tapper & Parikh, 2018). Although the relationship between education, BMI with ALD risk was controversial in this study, the majority of current studies support the associations between low education level, high BMI, and high ALD risk (Inan-Eroglu et al, 2022;Stroffolini et al, 2020;Wang et al, 2022). In addition, the finding that spirits drinkers, high drinking frequency, and long years of drinking duration were associated with a higher risk of ALD was also consistent with the previous study (Avila et al, 2020).…”

Section: F I G U R E 3 Sensitivity Analysismentioning

confidence: 61%

Risk factors and protective factors for alcohol‐related liver disease: A systematic review and meta‐analysis

Zhang

Tang

et al. 2022

Alcoholism Clin & Exp Res

View full text Add to dashboard Cite

Alcohol-related liver disease (ALD), a chronic liver disease associated with chronic excessive alcohol consumption, comprises simple steatosis, alcoholic hepatitis, liver fibrosis, cirrhosis, and liver cancer.High alcohol intake may induce extensive hepatocyte necrosis and even liver failure (2018). ALD has added a large disease burden on global public health. Roughly 60% of ALD patients are hospitalized for cirrhosis, alcoholic hepatitis, or both (Singal & Mathurin, 2021).Globally, alcohol-related cirrhosis causes more than a half million

show abstract

Joint associations of adiposity and alcohol consumption with liver disease-related morbidity and mortality risk: findings from the UK Biobank

Cited by 18 publications

References 38 publications

Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis: A cohort study

Long‐term exposure to air pollution and incident non‐alcoholic fatty liver disease and cirrhosis: A cohort study

Targeted therapeutics and novel signaling pathways in non-alcohol-associated fatty liver/steatohepatitis (NAFL/NASH)

Risk factors and protective factors for alcohol‐related liver disease: A systematic review and meta‐analysis

Contact Info

Product

Resources

About